Patent intelligence · US
US 10028949
Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
Patent details — US 10028949
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 24, 2018
- Expiration
- Jul 19, 2038
- Applicant
- Platform Brightworks Two, Ltd.
- Claims
- 22
- CPC classes
- A61K, A61K31/255, A61K31/496, A61K47/02
Quick answer
US 10028949 (Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same) is held by Platform Brightworks Two, Ltd.. Status: granted. Granted Jul 24, 2018. Expires Jul 19, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Platform Brightworks Two, Ltd.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/255, A61K31/496, A61K47/02, A61K47/10, A61K47/26
More from Platform Brightworks Two, Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 10028949?
US 10028949 (Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same) is held by Platform Brightworks Two, Ltd.. Status: granted. Granted Jul 24, 2018. Expires Jul 19, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10028949?
Platform Brightworks Two, Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 10028949 expire?
Our index shows an expiration date of Jul 19, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.